Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Pomalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention. Browse Pomalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
204
Shown on this page
12
Current sort
Recently updated
Therapy scope
Pomalidomide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Pomalidomide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 37–48 of 204 matching trials for Pomalidomide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional Results available

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

NCT05405166
View directory record Official record
Conditions
Plasma Cell Myeloma Recurrent
Interventions
Isatuximab IV, Isatuximab SC, Dexamethasone, Pomalidomide, Montelukast, Paracetamol / Acetaminophen, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Aurora, Colorado • Jacksonville, Florida • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Active, not recruiting Phase 1 Interventional

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

NCT02659930
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
liposomal doxorubicin, pomalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Active, not recruiting Phase 3 Interventional

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Recruiting Phase 1 Interventional

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

NCT05389423
View directory record Official record
Conditions
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell Neoplasm
Interventions
Vincristine, Prednisone, Doxorubicin, Etoposide, Pomalidomide, Cyclophosphamide, Rituximab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

NCT07227311
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
12
States / cities
Los Alamitos, California • Torrance, California • Whittier, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Daratumumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
26
States / cities
Clovis, California • Fresno, California • Fort Collins, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Recruiting Phase 3 Interventional

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
100
States / cities
Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Recruiting Phase 3 Interventional

Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

NCT07772024
View directory record Official record
Conditions
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Interventions
InoPd, Investigator's choice of SAT
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT05714839
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Bullhead City, Arizona • Los Angeles, California • Pembroke Pines, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945
View directory record Official record
Conditions
Multiple Myeloma
Interventions
AZD0305, Elranatamab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Recruiting Phase 1 Interventional

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

NCT05651932
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Myeloma Multiple
Interventions
Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®), Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
Drug
Lead sponsor
K36 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
17
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Etentamig, Dexamethasone, Lenalidomide, Pomalidomide, Daratumumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
15
States / cities
Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 21, 2026, 9:04 AM EDT

About this Pomalidomide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pomalidomide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Pomalidomide.